CMPX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About CMPX Interactive Breakdown Better Bets vs. CMPX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Compass Therapeutics (CMPX)

    Market Price (8/25/2026): $2.4 | Market Cap: $448.3 MilSector: Health Care | Industry: Biotechnology

    Compass Therapeutics (CMPX)

    Market Price (8/25/2026): $2.4
    Market Cap: $448.3 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.

    Weak multi-year price returns
    3Y Excs Rtn is -74%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -81 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%

    Significant short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.62, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%

    Key risks
    CMPX key risks include [1] the historically low success rate for its class of novel anti-angiogenic therapies and [2] a dependency on future financing due to its history of significant losses and lack of approved products.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
    2 Weak multi-year price returns
    3Y Excs Rtn is -74%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -81 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
    6 Significant short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.62, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%
    7 Key risks
    CMPX key risks include [1] the historically low success rate for its class of novel anti-angiogenic therapies and [2] a dependency on future financing due to its history of significant losses and lack of approved products.

    CMPX in ETFs

    Weight = CMPX's share of each fund

    VTI0.00%
    ITOT0.00%
    IWM0.01%
    XBI0.15%
    IWN0.02%
    VTWO0.01%
    VHT0.00%
    DFAS0.00%
    +3 more covered ETFs

    Valuation & Metrics

    FYE: 12/31CMPX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$39.3 Mil—
    FY 2027 Sales$23.3 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth-40.7%13.0%
    EARNINGS
    LTM Net Income (GAAP) [3]$-73.4 Mil—
    FY 2026 Net Income (Non-GAAP)$-90.7 Mil—
    FY 2027 Net Income (Non-GAAP)$-107.9 Mil—
    FY 2027 Net Income Growth—19.2%
    FY 2026 EPS (Non-GAAP)$-0.50—
    FY 2027 EPS (Non-GAAP)$-0.55—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S11.41.8
    FY 2027 P/S19.2—
    FY 2026 P/E—8.4
    FY 2027 P/E——

    [1] CMPX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 8/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Clinical Product Candidates311052025Link
    Number of Preclinical Product Candidates in IND Enabling Studies111052025Link
    Number of Granted U.S. Patents44292025Link
    Tovecimig (CTX-009) Clinical Trial PhasePhase 2/311052025Link
    CTX-8371 Clinical Trial PhasePhase 111052025Link
    CTX-471 Clinical Trial PhasePhase 211052025Link
    CTX-10726 Development StageIND Filing Planned11052025Link

    Price Chart

    null
    No Events

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 8/20/2026

    Compass Therapeutics (CMPX) stock has gained about 35% since 4/30/2026 because of the following key factors:

    1. Positive Phase 2/3 Clinical Data and Regulatory Progress for Tovecimig.

    Compass Therapeutics reported highly positive data from its Phase 2/3 COMPANION-002 study of tovecimig (a DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer. Announced in early May 2026, the data showed a statistically significant improvement in progression-free survival (PFS) from 2.6 months to 4.7 months (Hazard Ratio = 0.44, p<0.0001) for the combination of tovecimig and paclitaxel compared to paclitaxel alone. The overall response rate (ORR) also significantly improved from 5.3% to 17.1% (later updated to 18.0%, p=0.0228) in the combination arm. Additionally, tovecimig received Orphan Drug Designation in April 2026, and the company plans to engage with the FDA for a Biologics License Application (BLA) submission later in 2026. This positive clinical and regulatory advancement for its lead asset significantly contributed to the stock's trend.

    2. Encouraging Early-Stage Pipeline Data from CTX-8371.

    The presentation of promising Phase 1 clinical data for CTX-8371 (a PD-1 x PD-L1 bispecific antibody) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May and June 2026 further boosted investor confidence. The data highlighted promising monotherapy activity, with deep and durable responses observed in patients with advanced malignancies, including triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC). An overall response rate (ORR) of 33% was achieved at the two highest dose levels in evaluable patients, leading to the initiation of expansion cohorts for these indications. This provided additional validation for Compass Therapeutics' broader oncology pipeline.

    Show more
    Updated on 8/20/2026

    Compass Therapeutics (CMPX) stock has gained about 35% since 4/30/2026 because of the following key factors:

    1. Positive Phase 2/3 Clinical Data and Regulatory Progress for Tovecimig.

    Compass Therapeutics reported highly positive data from its Phase 2/3 COMPANION-002 study of tovecimig (a DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer. Announced in early May 2026, the data showed a statistically significant improvement in progression-free survival (PFS) from 2.6 months to 4.7 months (Hazard Ratio = 0.44, p<0.0001) for the combination of tovecimig and paclitaxel compared to paclitaxel alone. The overall response rate (ORR) also significantly improved from 5.3% to 17.1% (later updated to 18.0%, p=0.0228) in the combination arm. Additionally, tovecimig received Orphan Drug Designation in April 2026, and the company plans to engage with the FDA for a Biologics License Application (BLA) submission later in 2026. This positive clinical and regulatory advancement for its lead asset significantly contributed to the stock's trend.

    2. Encouraging Early-Stage Pipeline Data from CTX-8371.

    The presentation of promising Phase 1 clinical data for CTX-8371 (a PD-1 x PD-L1 bispecific antibody) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May and June 2026 further boosted investor confidence. The data highlighted promising monotherapy activity, with deep and durable responses observed in patients with advanced malignancies, including triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC). An overall response rate (ORR) of 33% was achieved at the two highest dose levels in evaluable patients, leading to the initiation of expansion cohorts for these indications. This provided additional validation for Compass Therapeutics' broader oncology pipeline.

    3. Solid Financial Runway.

    Compass Therapeutics maintained a strong financial position, reporting cash and marketable securities of $195 million at the end of fiscal Q1 2026 (ended March 31, 2026) and $180 million at the end of fiscal Q2 2026 (ended June 30, 2026). The company projects that this capital will fund its operations into 2028. This extended cash runway alleviated concerns regarding near-term financing needs and provided stability for the continued advancement of its clinical development programs.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The 35.6% change in CMPX stock from 4/30/2026 to 8/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)43020268242026Change
    Stock Price ($)1.772.4035.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)185187-0.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    4/30/2026 to 8/24/2026
    ReturnCorrelation
    CMPX35.6% 
    Market (SPY)6.2%32.0%
    Sector (XLV)19.7%29.3%

    Fundamental Drivers

    The -62.5% change in CMPX stock from 1/31/2026 to 8/24/2026 was primarily driven by a -9.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)13120268242026Change
    Stock Price ($)6.402.40-62.5%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)169187-9.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    1/31/2026 to 8/24/2026
    ReturnCorrelation
    CMPX-62.5% 
    Market (SPY)10.6%19.9%
    Sector (XLV)13.4%20.6%

    Fundamental Drivers

    The -19.2% change in CMPX stock from 7/31/2025 to 8/24/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).
    (LTM values as of)73120258242026Change
    Stock Price ($)2.972.40-19.2%
    Change Contribution By: 
    Total Revenues ($ Mil)10 
    P/S Multiple483.0∞9.2233720368547763E17%
    Shares Outstanding (Mil)138187-26.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2025 to 8/24/2026
    ReturnCorrelation
    CMPX-19.2% 
    Market (SPY)21.8%15.3%
    Sector (XLV)35.7%16.0%

    Fundamental Drivers

    The -16.4% change in CMPX stock from 7/31/2023 to 8/24/2026 was primarily driven by a -32.3% change in the company's Shares Outstanding (Mil).
    (LTM values as of)73120238242026Change
    Stock Price ($)2.872.40-16.4%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)126187-32.3%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2023 to 8/24/2026
    ReturnCorrelation
    CMPX-16.4% 
    Market (SPY)72.7%26.4%
    Sector (XLV)36.3%23.5%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    CMPX Return-20%59%-69%-7%270%-55%-40%
    Peers Return-14%-22%18%-9%7%58%22%
    S&P 500 Return27%-19%24%23%16%12%104%

    Monthly Win Rates [3]
    CMPX Win Rate0%58%8%42%67%38% 
    Peers Win Rate40%47%50%53%47%62% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    CMPX Max Drawdown--64%-74%-65%-63%-75% 
    Peers Max Drawdown-43%-50%-35%-46%-47%-25% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: XNCR, REGN, AMGN, MGNX, ZYME.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 8/24/2026 (YTD)

    How Low Can It Go

    EventCMPXS&P 500
    2025 US Tariff Shock
      % Loss-56.8%-18.8%
      % Gain to Breakeven131.5%23.1%
      Time to Breakeven146 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-44.4%-9.5%
      % Gain to Breakeven80.0%10.5%
      Time to Breakeven431 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-30.5%-6.7%
      % Gain to Breakeven43.9%7.1%
      Time to Breakeven657 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-64.3%-24.5%
      % Gain to Breakeven180.0%32.4%
      Time to Breakeven219 days427 days

    Compare to XNCR, REGN, AMGN, MGNX, ZYME

    In The Past

    Compass Therapeutics's stock fell -56.8% during the 2025 US Tariff Shock. Such a loss loss requires a 131.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventCMPXS&P 500
    2025 US Tariff Shock
      % Loss-56.8%-18.8%
      % Gain to Breakeven131.5%23.1%
      Time to Breakeven146 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-44.4%-9.5%
      % Gain to Breakeven80.0%10.5%
      Time to Breakeven431 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-30.5%-6.7%
      % Gain to Breakeven43.9%7.1%
      Time to Breakeven657 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-64.3%-24.5%
      % Gain to Breakeven180.0%32.4%
      Time to Breakeven219 days427 days

    Compare to XNCR, REGN, AMGN, MGNX, ZYME

    In The Past

    Compass Therapeutics's stock fell -56.8% during the 2025 US Tariff Shock. Such a loss loss requires a 131.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Compass Therapeutics (CMPX)

    ```html

    Compass Therapeutics (CMPX) is a clinical-stage biopharmaceutical company dedicated to developing innovative, proprietary antibody-based therapeutics specifically for the treatment of various human cancers. Based in Boston, Massachusetts, the company focuses on advancing novel drug candidates through clinical trials with the goal of addressing significant unmet medical needs in oncology.

    The company's pipeline features several key product candidates. CTX-009, an investigational bispecific antibody, is currently in Phase II clinical trials for biliary tract cancers and in Phase Ib trials for colorectal and ovarian cancers. Another promising candidate, CTX-471, is a monoclonal antibody undergoing Phase I clinical trials for patients with solid tumors, including small cell lung cancer and melanoma. Additionally, Compass is developing CTX-8371, a bispecific inhibitor targeting the PD-1 and PD-L1 pathways, further expanding its therapeutic efforts within the oncology market to serve patients with diverse and challenging tumor types.

    ```

    AI Analysis | Feedback

    Here are 1-3 brief analogies for Compass Therapeutics (CMPX):

    • A clinical-stage Amgen, but focused solely on cancer antibodies.
    • A nascent Genentech, pioneering antibody drugs for cancer.
    • The early-stage cancer therapeutics division of a future Bristol Myers Squibb.

    AI Analysis | Feedback

    ```html
    • CTX-009: An investigational bispecific antibody in clinical trials for biliary tract, colorectal, and ovarian cancers.
    • CTX-471: A monoclonal antibody product candidate undergoing Phase I clinical trial for various solid tumors, including small cell lung cancer and melanoma.
    • CTX-8371: A bispecific inhibitor designed to target PD-1 and PD-L1 within the oncology area.
    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Thomas J. Schuetz, MD, PhD Chief Executive Officer

    Thomas J. Schuetz co-founded Compass Therapeutics in 2014. He has over 20 years of experience in oncology, biopharmaceutical drug development, and life science venture investing. Prior to Compass, he was a venture partner at OrbiMed, where he co-founded Audentes Therapeutics, which was later acquired by Astellas. While at OrbiMed, he was involved in investments in and served as a director for Enobia Pharma (sold to Alexion), Relypsa (sold to Galenica), and Arteaus Therapeutics (sold to Eli Lilly). His previous roles also include chief medical officer of Therion Biologics Corporation and vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.

    Barry Shin, JD, MBA Chief Financial Officer

    Barry Shin was appointed Chief Financial Officer effective December 9, 2024. He brings over two decades of experience in the biopharmaceutical sector, having served as a public company executive, investment banker, and corporate attorney. Most recently, he was Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena, Inc. Previously, Mr. Shin was a Managing Director in the Healthcare Investment Banking Groups at Mizuho Securities and Guggenheim Securities, and also held a position at Piper Sandler.

    Arjun Prasad, MBA, MPH Chief Commercial Officer

    Arjun Prasad was appointed Chief Commercial Officer effective January 1, 2026. He has over 15 years of commercial experience in biotech and large pharma. Before joining Compass, Mr. Prasad served as Chief Commercial Officer at Servier Pharmaceuticals. His experience also includes leadership roles at Agios Pharmaceuticals and Genentech, and he has been involved in over 10 oncology product launches.

    Cynthia Sirard, MD Chief Medical Officer

    Cynthia Sirard was appointed Chief Medical Officer effective January 1, 2026. Prior to Compass, she was Chief Medical Officer at Leap Therapeutics. Dr. Sirard also has clinical development leadership experience from her time at Sanofi and Genzyme. She is a gastrointestinal-focused medical oncologist who trained at Harvard Medical School's Beth Israel Deaconess Medical Center.

    AI Analysis | Feedback

    The key risks to Compass Therapeutics (CMPX), a clinical-stage oncology-focused biopharmaceutical company, are primarily centered around the success of its drug development pipeline, financial sustainability, and market competition.

    1. Clinical Trial Failure and Regulatory Approval: As a clinical-stage company, Compass Therapeutics' viability is heavily dependent on the successful completion of its clinical trials and obtaining regulatory approvals for its product candidates. The drug development process is lengthy, expensive, and inherently unpredictable, with a high rate of failure at various stages. For instance, historically, only a small percentage of developmental candidates successfully progress through Phase 2 and Phase 3 trials. The company's lead product candidate, CTX-009, is in Phase II/III trials, and the story could change quickly if these key trials disappoint. Furthermore, even if trials are successful, the regulatory approval processes by authorities like the FDA are time-consuming and uncertain, and failure to obtain approval would materially harm the business.
    2. Funding and Cash Burn: Compass Therapeutics consistently incurs significant net losses due to substantial research and development expenditures. For example, the company reported a net loss of US$66.49 million in 2025. This necessitates a continued reliance on external financing, often through equity offerings, which can lead to dilution for existing shareholders. While the company had approximately $209 million in cash and marketable securities as of December 31, 2025, expected to fund operations into 2028, the ongoing cash burn and the need to secure additional funding to advance its pipeline remain a central risk.
    3. Competition: The biotechnology and pharmaceutical industries are highly competitive. Compass Therapeutics faces significant competition from other companies developing similar antibody-based therapeutics and oncology treatments. The ability to compete effectively against established and emerging players is crucial for the company's operating results and the market acceptance of any approved products.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Compass Therapeutics, Inc. develops antibody-based therapeutics for various human diseases, primarily focusing on oncology. The addressable markets for its main products are detailed below:

    CTX-009

    • Biliary Tract Cancers: The global biliary tract cancer market size is projected to reach approximately $1.01 billion by 2030. Another estimate indicates the global market size is expected to grow from USD 0.675 billion in 2024 to USD 1.067 billion by 2035. The total market size for biliary tract cancer in the 7 Major Markets (7MM: United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan) was approximately USD 1.16 billion in 2024. In the United States alone, the market was approximately USD 700 million in 2024.
    • Colorectal Cancer: The global colorectal cancer market size was valued at approximately $13 billion in 2023 and is anticipated to reach $20 billion by the end of 2032. Another report estimates the global market to be valued at USD 13.74 billion in 2025 and reach USD 19.08 billion by 2032. The total colorectal cancer market size across the 7MM was approximately USD 13,000 million in 2023. North America held a significant share, accounting for about 64.3% of the global market size in 2023.
    • Ovarian Cancer: The global ovarian cancer drugs market generated USD 3,611.0 million in revenue in 2023 and is expected to reach USD 5,654.6 million by 2030. Another source reported the global ovarian cancer market size to be USD 3.5 billion in 2023, with a projection to reach approximately USD 6.5 billion by 2032. The ovarian cancer market size in the 7MM is expected to grow from USD 3,012 million in 2025 to USD 5,703 million in 2034. North America was the largest revenue-generating market in 2023, accounting for over 40% of the global market share. The US alone accounted for nearly USD 1,922 million in 2024 in the 7MM.

    CTX-471

    • Small Cell Lung Cancer: The global small cell lung cancer therapeutics market size is valued at USD 7.25 billion in 2025 and is predicted to increase to approximately USD 22.86 billion by 2035. Another projection indicates the global market will grow from USD 6.91 billion in 2025 to USD 12.75 billion by 2031. The small cell lung cancer market in the 7MM reached a value of USD 8.9 billion in 2024 and is expected to reach USD 23.0 billion by 2035. The U.S. small cell lung cancer treatment market is estimated to be valued at USD 527.0 million in 2025 and is anticipated to reach USD 1.5 billion by 2035.
    • Melanoma: The global melanoma therapeutics market size was valued at USD 4.62 billion in 2024, is predicted to be USD 5.32 billion in 2025, and is expected to be worth USD 17.30 billion by 2033. Other estimates for the global market size include USD 5.83 billion in 2024, reaching USD 10.26 billion by 2030, and USD 7.39 billion in 2025, reaching around USD 17.93 billion by 2034. North America accounted for the largest share of the global melanoma therapeutics market, leading with a 41% market share in 2024. The U.S. melanoma therapeutics market was valued at USD 0.52 billion in 2023 and is expected to reach USD 1.14 billion by 2032.

    CTX-8371

    • PD-1 and PD-L1 Inhibitors (Oncology): The global PD-1 and PD-L1 inhibitors market size is forecast to increase by USD 49.3 billion at a compound annual growth rate (CAGR) of 18.3% between 2023 and 2028. The market size was valued at USD 49.15 billion in 2024 and is poised to grow to USD 209.83 billion by 2033. Another report estimates the market size at USD 63.73 billion in 2025, expected to reach USD 145.56 billion by 2030. North America currently dominates the global PD-1/PD-L1 inhibitors market, accounting for 43.21% of the revenue in 2025.

    AI Analysis | Feedback

    Here are 3-5 expected drivers of future revenue growth for Compass Therapeutics (CMPX) over the next 2-3 years:

    1. Potential Commercialization of Tovecimig (CTX-009) in Biliary Tract Cancer (BTC): Compass Therapeutics' lead investigational bispecific antibody, tovecimig (CTX-009), is in a Phase 2/3 clinical trial for biliary tract cancers. The company anticipated pivotal progression-free survival and overall survival analyses from the COMPANION-002 study in late first quarter 2026. Tovecimig met its primary efficacy endpoint in April 2025, and Compass Therapeutics aims to file with regulators later in 2026. Successful regulatory approval and subsequent launch in this market, estimated to be around $1.4 billion annually in the U.S., would be a significant driver of revenue.
    2. Expansion of Tovecimig (CTX-009) into Additional Indications: Beyond biliary tract cancer, tovecimig is also being developed for other indications. A Phase 2 study in patients with DLL4-positive colorectal cancer was expected to initiate in mid-2025, with additional Phase 2 monotherapy data in metastatic colorectal cancer showcased at the 2026 ASCO GI Cancers Symposium, demonstrating differentiated activity. Success in expanding the approved indications for tovecimig would broaden its market reach and revenue potential.
    3. Advancement and Potential Commercialization of CTX-471: CTX-471, a monoclonal antibody, is in Phase I clinical trials for solid tumors. A Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is expected to begin in the first quarter of 2026. [cite: BACKGROUND, 20] Promising clinical responses and a correlation between NCAM expression and disease control have been observed in earlier studies, positioning CTX-471 as a potential revenue contributor if clinical development continues positively.
    4. Progression of CTX-8371 through Clinical Trials: CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, is undergoing a Phase 1 clinical trial. Preliminary data was expected in the second half of 2025, and encouraging early clinical signals, including durable responses in triple-negative breast cancer and Hodgkin lymphoma, have led to cohort expansions in these areas. [cite: BACKGROUND, 13, 17, 25] Results from the fifth cohort are anticipated to be presented at a major medical conference in the first half of 2026. Continued positive data and advancement to later-stage trials or accelerated pathways could pave the way for future revenue.
    5. Initiation of CTX-10726 Clinical Trials: Compass Therapeutics is advancing CTX-10726, a novel PD-1 x VEGF-A bispecific antibody, with an Investigational New Drug (IND) application expected by the end of 2025 and initial proof-of-concept clinical data anticipated in 2026. The company planned to initiate a Phase 1 study of CTX-10726 in the first quarter of 2026. Preclinical data indicating superior tumor control compared to a competitor suggests significant potential for this new product candidate to contribute to future revenue if clinical development is successful.

    AI Analysis | Feedback

    Capital Allocation Decisions for Compass Therapeutics (CMPX)

    Share Issuance

    • Compass Therapeutics' shares outstanding have shown consistent growth, increasing from 61.69 million in 2021 to 180.09 million by March 2026.
    • In August 2025, Compass Therapeutics priced a $120 million stock offering.

    Inbound Investments

    • As of the latest reports, 200 institutional owners hold a total of 163,725,703 shares in Compass Therapeutics.
    • Significant institutional shareholders include Tang Capital Management Llc, Orbimed Advisors Llc, and BlackRock, Inc.
    • BlackRock, Inc. reported a 5.2% passive stake in the company as of January 21, 2026.

    Capital Expenditures

    • Capital expenditures in the most recent quarter (Q4 2025) totaled -$0.007 million USD.
    • For the full fiscal year 2025, capital expenditures were reported as $25,000.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that CMPX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    39%
    of 460 industry peers · -20.5% return
    3Y
    59%
    of 406 industry peers · 1.3% return
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is CMPX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 11.5%85.0%132.2% CAH 400% · MCK 348% · COR 189%
    Health Care Services 20 20.9%46.0%3.9% HIMS 314% · RDNT 146% · DGX 80%
    Managed Health Care 8 32.1%-1.6%3.5% OSCR 143% · HQY 64% · ELV 16%
    Health Care Facilities 24 7.9%-2.8%-17.5% THC 278% · NHC 257% · ENSG 125%
    Health Care Equipment 50 -2.9%-6.1%-21.0% POCI 10987% · UFPT 367% · GKOS 253%
    Health Care Supplies 12 34.1%-12.7%-32.6% LNTH 301% · HAE 81% · MMSI 30%
    Pharmaceuticals 63 4.3%6.4%-37.4% LQDA 2532% · INDV 1260% · ETON 1176%
    Life Sciences Tools & Services 108 -3.6%-28.4%-72.7% SNWV 1827% · ELMD 249% · MEDP 243%
    Health Care Technology 21 -21.8%-55.6%-74.4% SPOK 125% · HSTM -1% · VEEV -24%
    Biotechnology ← 365 7.1%-26.0%-78.7% BRTX 106500% · CELZ 1629% · DNTH 1519%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Compass Therapeutics Earnings Notes12/16/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    MRNAModerna54.9115.5%371.0%
    AMLXAmylyx Pharmaceuticals4.278.0%215.8%
    EMATEvolution Metals & Technologies2.650.9%-80.2%
    ASSTStrive1.249.5%33.7%
    PURRHyperliquid Strategies1.348.8%198.9%
    MRVIMaravai LifeSciences1.248.4%159.4%
    WEAVWeave Communications0.631.8%-4.0%
    BMNRBitMine Immersion Technologies13.328.9%-11.1%
    TEMTempus AI11.828.1%12.1%
    XXITwenty One Capital4.127.5%-28.0%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AEHRAehr Test Systems3.0-33.8%377.6%
    AXTIAXT3.5-31.9%300.0%
    AEVAAeva Technologies1.0-30.7%23.9%
    AAOIApplied Optoelectronics8.2-30.5%208.7%
    FNFabrinet15.1-29.6%-7.5%
    WOLFWolfspeed1.0-29.2%42.2%
    RGNXRegenxbio0.4-28.9%-44.1%
    AMRCAmeresco1.1-26.4%-28.4%
    FEIMFrequency Electronics0.6-26.0%8.4%
    MXLMaxLinear5.7-25.9%260.2%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MRNAModerna54.9156.9%371.0%
    HTFLHeartFlow4.3108.1%72.2%
    AMLXAmylyx Pharmaceuticals4.2107.2%215.8%
    ABCLAbCellera Biologics3.299.8%210.2%
    LIFEEthos Technologies1.898.5%4353.1%
    OMEROmeros1.497.3%12.5%
    TEAMAtlassian44.797.2%5.7%
    NIQNIQ Global Intelligence5.778.4%16.3%
    PURRHyperliquid Strategies1.371.9%198.9%
    ASSTStrive1.271.7%33.7%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SIONSionna Therapeutics0.3-87.8%-86.4%
    TENXTenax Therapeutics0.1-87.3%-84.8%
    MPLTMapLight Therapeutics0.5-68.9%-35.3%
    EYPTEyePoint0.4-60.0%-73.3%
    TDUPThredUp0.4-50.7%-56.0%
    AHCOAdaptHealth0.8-47.7%-43.5%
    KLCKinderCare Learning Companies0.3-47.1%-39.6%
    REZIResideo Technologies2.9-44.2%-45.1%
    LMBLimbach0.5-42.7%-46.4%
    UTIUniversal Technical Institute1.2-41.7%-15.7%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    CMPXXNCRREGNAMGNMGNXZYMEMedian
    NameCompass .Xencor Regenero.Amgen Macrogen.Zymeworks 
    Mkt Price2.4029.00828.50443.844.0228.7728.88
    Mkt Cap0.42.285.2239.70.32.12.1
    Rev LTM010515,53538,09516837136
    Op Inc LTM-81-2164,17411,426-41-155-61
    FCF LTM-56-2083,57510,175-66-121-61
    FCF 3Y Avg-48-1633,4398,754-99-86-67
    CFO LTM-56-2064,68112,478-64-119-60
    CFO 3Y Avg-48-1574,49810,312-96-83-66

    Growth & Margins

    CMPXXNCRREGNAMGNMGNXZYMEMedian
    NameCompass .Xencor Regenero.Amgen Macrogen.Zymeworks 
    Rev Chg LTM--28.6%9.3%9.1%11.7%-69.8%9.1%
    Rev Chg 3Y Avg-0.6%7.0%12.8%68.3%-19.9%7.0%
    Rev Chg Q-17.5%16.7%9.5%378.0%-90.6%16.7%
    QoQ Delta Rev Chg LTM-7.8%4.1%2.4%18.3%-54.3%4.1%
    Op Inc Chg LTM-19.5%-49.3%6.1%39.5%51.8%-87.9%-6.7%
    Op Inc Chg 3Y Avg-18.7%-11.7%-1.7%12.3%1.5%-73.6%-6.7%
    Op Mgn LTM--205.8%26.9%30.0%-24.3%-418.8%-24.3%
    Op Mgn 3Y Avg--136.0%28.2%24.5%-186.8%-225.9%-136.0%
    QoQ Delta Op Mgn LTM-12.1%1.1%1.6%25.2%-278.5%1.6%
    CFO/Rev LTM--196.1%30.1%32.8%-38.0%-321.4%-38.0%
    CFO/Rev 3Y Avg--124.6%31.2%29.3%-153.4%-166.2%-124.6%
    FCF/Rev LTM--198.4%23.0%26.7%-39.1%-325.1%-39.1%
    FCF/Rev 3Y Avg--129.1%23.9%24.9%-157.2%-170.6%-129.1%

    Valuation

    CMPXXNCRREGNAMGNMGNXZYMEMedian
    NameCompass .Xencor Regenero.Amgen Macrogen.Zymeworks 
    Mkt Cap0.42.285.2239.70.32.12.1
    P/S-21.05.56.31.556.66.3
    P/Op Inc-5.5-10.220.421.0-6.3-13.5-5.9
    P/EBIT-5.5-16.416.318.5-2.9-14.1-4.2
    P/E-6.1-13.519.727.4-17.5-14.0-9.8
    P/CFO-8.0-10.718.219.2-4.0-17.6-6.0
    Total Yield-16.4%-7.4%5.5%5.9%-5.7%-7.1%-6.4%
    Dividend Yield0.0%0.0%0.4%2.2%0.0%0.0%0.0%
    FCF Yield 3Y Avg-19.2%-17.6%4.9%5.2%-59.6%-8.5%-13.0%
    D/E0.00.10.00.20.10.00.1
    Net D/E-0.4-0.1-0.10.2-0.5-0.1-0.1

    Returns

    CMPXXNCRREGNAMGNMGNXZYMEMedian
    NameCompass .Xencor Regenero.Amgen Macrogen.Zymeworks 
    1M Rtn15.9%49.2%26.4%18.7%8.6%25.9%22.3%
    3M Rtn15.9%156.4%29.8%31.6%-11.3%12.3%22.9%
    6M Rtn-59.3%150.6%5.5%18.6%129.7%25.1%21.8%
    12M Rtn-20.5%244.8%41.3%55.3%137.9%90.5%72.9%
    3Y Rtn1.3%28.3%0.7%89.4%-20.4%273.6%14.8%
    1M Excs Rtn12.7%45.9%23.2%15.5%5.4%22.6%19.0%
    3M Excs Rtn13.5%154.0%27.4%29.2%-13.7%9.9%20.5%
    6M Excs Rtn-71.2%138.7%-6.4%6.6%117.8%13.2%9.9%
    12M Excs Rtn-34.4%269.6%19.1%35.3%159.0%79.8%57.6%
    3Y Excs Rtn-74.3%-45.8%-70.1%8.9%-93.6%216.3%-58.0%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/6/20265/5/20263/5/202611/5/20258/11/20255/8/20252/27/202511/12/20248/12/20245/13/20243/21/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000001000
    Ebitda-27-20-18-15-21-18-16-12-15-12-15-11
    Operating Income-27-20-18-16-21-18-17-12-15-13-15-12
    Net Income-25-18-16-14-20-17-15-10-13-11-13-10
    EPS-0.13-0.10-0.09-0.08-0.14-0.12-0.11-0.08-0.10-0.08-0.10-0.08
    Key Financials TTM            
    Total Revenue TTM000001111000
    Ebitda TTM-80-74-71-70-66-60-55-54-53-52-48-46
    Operating Income TTM-81-75-73-71-68-62-57-55-55-53-50-48
    Net Income TTM-73-68-66-66-62-55-49-48-47-45-42-41
    Growth Rates Quarterly            
    Total Revenue Growth-----100.0%-------
    EBITDA Growth-28.5%-13.2%-8.7%-31.2%-42.0%-43.0%-8.6%-2.7%-13.3%-33.3%-20.3%5.4%
    Operating Income Growth-28.1%-13.0%-8.5%-29.2%-40.0%-40.7%-7.7%-2.6%-12.8%-31.5%-19.4%5.3%
    Net Income Growth-26.5%-10.1%-4.5%-36.0%-52.0%-54.2%-12.1%-5.2%-15.9%-37.6%-15.7%16.8%
    Margins Quarterly            
    EBITDA Margin---------1715.2%---
    Operating Income Margin---------1770.0%---
    Net Income Margin---------1538.4%---
    Cash & Debt            
    Total Cash180195209220101113127135146156152164
    Total Debt10101010106771122
    Net Debt / (Cash)-170-185-199-210-91-106-120-129-145-155-151-162
    Cash Flows Quarterly            
    FCF from Operations-15-17-13-11-12-13-9-11-11-14-12-6
    Cash Flows TTM            
    FCF from Operations TTM-56-53-49-45-45-44-45-48-43-42-41-39
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-22.9%-18.0%-16.8%-15.2%-20.9%-18.6%-17.9%-13.6%-17.7%-15.6%-19.7%-15.9%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-17.2%-16.7%-17.0%-17.2%-16.8%-16.0%-15.3%-15.4%-16.2%-16.3%-16.1%-15.9%

    Segment Financials

    Revenue by Segment
    $ Mil202520242023
    Research and development of drug candidates010
    Total010


    Net Income by Segment
    $ Mil20252024
    Research and development of drug candidates-66-49
    Total-66-49


    Assets by Segment
    $ Mil20232022202120202019
    Research and development of drug candidates1572001545230
    Total1572001545230


    Price Behavior

    Price Behavior
    Market Price$2.40 
    Market Cap ($ Bil)0.4 
    First Trading Date11/02/2021 
    Distance from 52W High-64.1% 
       50 Days200 Days
    DMA Price$2.16$4.07
    DMA Trenddownup
    Distance from DMA11.3%-41.0%
     3M1YR
    Volatility54.9%89.6%
    Downside Capture41.89105.23
    Upside Capture105.7056.77
    Correlation (SPY)31.8%17.9%
    CMPX Betas & Captures as of 7/31/2026

     1M2M3M6M1Y3Y
    Beta0.591.051.431.481.081.52
    Up Beta1.482.691.112.451.721.34
    Down Beta1.511.882.081.471.251.53
    Up Capture-95%-45%138%-46%14%232%
    Bmk +ve Days11223567138427
    Stock +ve Days8203261128355
    Down Capture111%92%118%177%95%110%
    Bmk -ve Days11212859114326
    Stock -ve Days13222962113361

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CMPX
    CMPX-14.3%89.6%0.43-
    Sector ETF (XLV)29.3%16.0%1.4117.9%
    Equity (SPY)21.2%12.9%1.2317.8%
    Gold (GLD)39.0%28.8%1.1410.5%
    Commodities (DBC)40.9%20.2%1.58-7.4%
    Real Estate (VNQ)13.9%13.8%0.7013.0%
    Bitcoin (BTCUSD)-30.4%44.2%-0.699.4%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CMPX
    CMPX-9.8%86.3%0.30-
    Sector ETF (XLV)6.9%15.1%0.2719.1%
    Equity (SPY)12.8%17.2%0.5719.9%
    Gold (GLD)20.6%18.6%0.906.9%
    Commodities (DBC)10.2%19.6%0.413.4%
    Real Estate (VNQ)2.4%18.9%0.0218.2%
    Bitcoin (BTCUSD)11.2%52.8%0.4013.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CMPX
    CMPX-5.0%86.3%0.30-
    Sector ETF (XLV)10.7%16.7%0.5219.1%
    Equity (SPY)15.1%17.9%0.7219.9%
    Gold (GLD)12.9%16.3%0.656.9%
    Commodities (DBC)7.8%18.1%0.353.4%
    Real Estate (VNQ)5.0%20.7%0.2018.2%
    Bitcoin (BTCUSD)63.1%66.2%1.0313.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date7312026
    Short Interest: Shares Quantity39.9 Mil
    Short Interest: % Change Since 71520261.5%
    Average Daily Volume2.3 Mil
    Days-to-Cover Short Interest17.6 days
    Basic Shares Quantity186.8 Mil
    Short % of Basic Shares21.3%

    Earnings Returns History

    Updated 8/17/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/20265.3%25.4% 
    5/5/20260.5%-5.7%8.2%
    3/5/2026-2.8%-1.8%-4.2%
    1/6/2026-1.6%4.4%26.9%
    11/5/20250.8%22.2%45.9%
    8/11/202523.7%10.0%28.9%
    5/8/20251.1%13.6%42.0%
    2/27/2025-1.7%-6.7%-29.3%
    ...
    SUMMARY STATS   
    # Positive10118
    # Negative768
    Median Positive4.4%12.3%35.5%
    Median Negative-2.5%-6.2%-17.3%
    Max Positive30.1%72.7%144.8%
    Max Negative-6.4%-28.9%-30.7%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/20265.3%25.4% 
    5/5/20260.5%-5.7%8.2%
    3/5/2026-2.8%-1.8%-4.2%
    1/6/2026-1.6%4.4%26.9%
    11/5/20250.8%22.2%45.9%
    8/11/202523.7%10.0%28.9%
    5/8/20251.1%13.6%42.0%
    2/27/2025-1.7%-6.7%-29.3%
    1/8/202530.1%72.7%144.8%
    11/12/2024-5.8%-28.9%-12.1%
    8/12/20243.7%6.4%45.0%
    5/13/2024-2.5%0.0%-23.8%
    3/21/20245.7%-3.3%-30.7%
    1/5/20245.2%14.2%-22.6%
    11/9/2023-6.4%-14.0%1.2%
    8/3/20231.5%0.4%-11.1%
    5/4/2023-1.3%12.3%-1.8%
    SUMMARY STATS   
    # Positive10118
    # Negative768
    Median Positive4.4%12.3%35.5%
    Median Negative-2.5%-6.2%-17.3%
    Max Positive30.1%72.7%144.8%
    Max Negative-6.4%-28.9%-30.7%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/05/202610-Q
    12/31/202503/05/202610-K
    09/30/202511/05/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/08/202510-Q
    12/31/202402/27/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/12/202410-Q
    03/31/202405/13/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/03/202310-Q
    03/31/202305/04/202310-Q
    12/31/202203/15/202310-K
    09/30/202211/09/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/05/202610-Q
    12/31/202503/05/202610-K
    09/30/202511/05/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/08/202510-Q
    12/31/202402/27/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/12/202410-Q
    03/31/202405/13/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/03/202310-Q
    03/31/202305/04/202310-Q
    12/31/202203/15/202310-K
    09/30/202211/09/202210-Q
    06/30/202208/01/202210-Q
    03/31/202205/09/202210-Q
    12/31/202103/18/202210-K
    09/30/202111/12/202110-Q
    06/30/202108/16/202110-Q
    03/31/202104/30/202110-Q
    12/31/202003/11/2021424B3
    09/30/202011/09/2020S-1/A
    06/30/202010/19/2020S-1

    Insider Activity

    Updated 4/29/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Schuetz, Thomas JCHIEF EXECUTIVE OFFICERDirectBuy52720252.1110,00021,10013,674,541Form
    2Gordon, Carl LSee footnotesSell41120251.593,571,428  Form
    3Orbimed, Advisors LlcSee footnotesSell41120251.593,571,428  Form
    4Anderman, JonathanGen Counsel & Corporate SecDirectBuy40820251.5420,00030,80032,340Form
    5Lerner, NeilCHIEF ACCOUNTING OFFICERDirectBuy40820251.4220,00028,400454,400Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Schuetz, Thomas JCHIEF EXECUTIVE OFFICERDirectBuy52720252.1110,00021,10013,674,541Form
    2Gordon, Carl LSee footnotesSell41120251.593,571,428  Form
    3Orbimed, Advisors LlcSee footnotesSell41120251.593,571,428  Form
    4Anderman, JonathanGen Counsel & Corporate SecDirectBuy40820251.5420,00030,80032,340Form
    5Lerner, NeilCHIEF ACCOUNTING OFFICERDirectBuy40820251.4220,00028,400454,400Form

    Investor Activity (13F)

    Updated Aug 25, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Enavate Sciences GP, LLC$41.2 Mil11.7%7Hold13F
    Vivo Capital, LLC$50.5 Mil4.2%46Hold13F
    Great Point Partners LLC$7.1 Mil1.7%39New13F
    BVF Inc/Il$41.1 Mil1.3%41Hold13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Great Point Partners LLC$7.1 Mil1.7%39New13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Trails Edge Capital Partners, LP$7.6 Mil1.9%23Exited13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Vivo Capital, LLC$50.5 Mil4.2%46Hold13F
    Enavate Sciences GP, LLC$41.2 Mil11.7%7Hold13F
    BVF Inc/Il$41.1 Mil1.3%41Hold13F
    Great Point Partners LLC$7.1 Mil1.7%39New13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 8/24/2026